Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists

@article{Albanese2003DihydroergocriptineIP,
  title={Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists},
  author={A. Albanese and C. Colosimo},
  journal={Acta Neurologica Scandinavica},
  year={2003},
  volume={107}
}
The present paper reviews clinical studies on the use of dihydroergocriptine (DHEC), an ergot derivative with dopamine agonist activity, for the treatment of Parkinson's disease. This compound is a hydrogenated ergot derivative structurally quite similar to bromocriptine, from which it differs because of the hydrogenation in C9–C10 and the lack of bromine in C2. DHEC has a potent D2‐like receptor agonist and a partial D1‐like receptor agonist activity; because of this biochemical profile, it… Expand
Synergistic effect of α-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture
Dopamine receptor agonists in the therapy of Parkinson’s disease
Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson’s Disease
Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease
  • D. Nyholm
  • Medicine
  • Clinical pharmacokinetics
  • 2006
Current and future therapeutic approaches in progressive supranuclear palsy.
...
1
2
...

References

SHOWING 1-10 OF 55 REFERENCES
Clinical usefulness of apomorphine in movement disorders.
Treatment of restless legs syndrome with the dopamine agonist alpha‐dihydroergocryptine
  • Frithjof Tergau, Stephan Wischer, C. Wolf, W. Paulus
  • Psychology, Medicine
  • Movement disorders : official journal of the Movement Disorder Society
  • 2001
A rationale for dopamine agonists as primary therapy for Parkinson's disease.
  • C. Olanow
  • Medicine
  • The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • 1992
...
1
2
3
4
5
...